Nimesulide is a patented product of Helsinn Company of Switzerland. It was first listed in Italy in 1985, and has been used in more than 5 countries, with a market scale of over US$ 1 billion. There have been some twists and turns in the development of nimesulide, and many questions have been clarified through large-scale clinical research and scientific analysis. Nimesulide memorabilia will help to understand the whole picture of Nimesulide products. Nimesulide is a nonsteroidal anti-inflammatory drug. It can selectively inhibit cyclooxygenase ⅱ, so it has obvious anti-inflammatory, analgesic and antipyretic effects. There are a lot of clinical documents at home and abroad, which show that nimesulide has a faster antipyretic and analgesic effect than ibuprofen and acetaminophen, and its adverse reactions are equivalent. On November 26, 21, at the Beijing International Forum on Children's Drug Safety, relevant medical personnel reminded that nimesulide should be used with caution in the choice of drugs for children's fever, and cases of central nervous system and liver damage caused by this drug often appear. On May 2, 211, the State Food and Drug Administration issued a notice to amend the instructions of nimesulide, and banned nimesulide oral preparations from being used in children under the age of 12.